Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Key claim: A Phase 2 trial is evaluating whether momelotinib combined with luspatercept improves outcomes in transfusion-dependent myelofibrosis patients who are JAK inhibitor naïve or experienced.
Abstract
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Why this matters
Transfusion-dependent anemia is a defining problem in advanced PMF and post-PV/post-ET MF, yet most JAK inhibitors worsen cytopenias; momelotinib (which uniquely improves anemia via ACVR1/hepcidin suppression) paired with luspatercept (an erythroid maturation agent active in MDS and beta-thalassemia) tests whether two complementary anemia-directed mechanisms can be layered. This is the first prospective evaluation of this combination and addresses an MF subpopulation where transfusion independence is both a meaningful clinical endpoint and a prognostic marker. It also expands the menu of mechanism-paired ruxolitinib alternatives being tested specifically in the cytopenic/anemic MF subtype niche.